{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:52:17Z","timestamp":1778543537006,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beha.2020.101150","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T11:42:26Z","timestamp":1579261346000},"page":"101150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies\u2014back to the future!"],"prefix":"10.1016","volume":"33","author":[{"given":"Dickran","family":"Kazandjian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Dew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2020.101150_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib2","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.beha.2020.101150_bib3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","article-title":"A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib5","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.seminoncol.2019.03.001","article-title":"State of the science in smoldering myeloma: should we be treating in the clinic?","volume":"46","author":"Hill","year":"2019","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2020.101150_bib7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib8","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol.0:JCO.19.01740."},{"key":"10.1016\/j.beha.2020.101150_bib9","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib10","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1001\/jama.296.12.1518","article-title":"An anniversary for cancer chemotherapy","volume":"296","author":"Hirsch","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.beha.2020.101150_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.beha.2020.101150_bib12","first-page":"6","article-title":"Cytotoxic alpha amino acids and peptides","volume":"31","author":"Bergel","year":"1953","journal-title":"Br Emp Cancer Campain"},{"key":"10.1016\/j.beha.2020.101150_bib13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"Clinical experiences with SARCOLYSIN IN neoplastic diseases","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.beha.2020.101150_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation. Biology of blood and marrow transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2020.101150_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","article-title":"Multiple myeloma treated with high dose intravenous melphalan","volume":"66","author":"Selby","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2020.101150_bib16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2020.101150_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib19","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib20","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib21","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2002-03-0889","article-title":"Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study","volume":"101","author":"Segeren","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib22","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib23","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 Years: long-term results of a randomized control trial from the group myelome-autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib24","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2020.101150_bib27","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib29","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood.V128.22.675.675","article-title":"Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)","volume":"128","author":"Zimmerman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib31","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1182\/blood.V128.22.4527.4527","volume":"128","author":"Kazandjian","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial","author":"Kazandjian","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib33","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib34","series-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial","author":"Francesca Gay","year":"2019"},{"key":"10.1016\/j.beha.2020.101150_bib35","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"The Oncologist"},{"key":"10.1016\/j.beha.2020.101150_bib36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib38","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib39","series-title":"17th international myeloma workshop. Boston, MA","article-title":"Daratumumab + lenalidomide, bortezomib & dexamethasone improves depth of response in transplant-eligible newly diagnosed multiple myeloma: GRIFFIN","author":"Peter Voorhees","year":"2019"},{"key":"10.1016\/j.beha.2020.101150_bib40","series-title":"61st annual meeting of the American association of hematology. Orlando, FL","article-title":"Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a clinical and correlative phase 2 study","author":"Ola Landgren","year":"2019"},{"key":"10.1016\/j.beha.2020.101150_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/beha.2002.0192","article-title":"Minimal residual disease monitoring in multiple myeloma","volume":"15","author":"Davies","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2020.101150_bib42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V128.22.245.245","article-title":"Impact of minimal residual disease in transplant ineligible myeloma patients: results from the UK NCRI myeloma XI trial","volume":"128","author":"de Tute","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2018.03.003","article-title":"MRD testing in multiple myeloma: from a surrogate marker of clinical outcomes to an every-day clinical tool","volume":"55","author":"Landgren","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2020.101150_bib44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases","volume":"38","author":"Tembhare","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2020.101150_bib45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2020.101150_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytom B Clin Cytom"},{"key":"10.1016\/j.beha.2020.101150_bib47","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib48","unstructured":"Administration UFaD. FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma."},{"key":"10.1016\/j.beha.2020.101150_bib49","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2020.101150_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2020.101150_bib51","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","author":"Munshi","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/asheducation.V2014.1.255.3885263","article-title":"Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?","volume":"2014","author":"Richardson","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.beha.2020.101150_bib54","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2017-05-693606","article-title":"How I treat the young patient with multiple myeloma","volume":"132","author":"Gandolfi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib55","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbmt.2017.03.012","article-title":"In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study","volume":"23","author":"Sanchez","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2020.101150_bib56","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood.V124.21.3978.3978","article-title":"Utilization trend and in-hospital complications of autologous hematopoietic stem cell transplantation in multiple myeloma in the United States: 13 Years perspective","volume":"124","author":"Savani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib57","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/cncr.23281","article-title":"In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies","volume":"112","author":"Jones","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2020.101150_bib58","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbmt.2012.09.023","article-title":"Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biology of blood and marrow transplantation","volume":"19","author":"Krishnan","year":"2013","journal-title":"J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2020.101150_bib59","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Canc"},{"key":"10.1016\/j.beha.2020.101150_bib60","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbmt.2014.12.028","article-title":"New cancers after autotransplantations for multiple myeloma","volume":"21","author":"Mahindra","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2020.101150_bib61","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib62","unstructured":"Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res."},{"key":"10.1016\/j.beha.2020.101150_bib63","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib64","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib65","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib66","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101150_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib68","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","article-title":"Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM","volume":"2","author":"Jagannath","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2020.101150_bib69","series-title":"Clinical practice guidelines multiple myeloma","author":"Network NCC","year":"2019"},{"key":"10.1016\/j.beha.2020.101150_bib70","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO Joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101150_bib71","first-page":"747","article-title":"Point\/counterpoint: routine use of autologous stem cell transplantation in multiple myeloma. One size does not fit all","volume":"30","author":"Richardson","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.beha.2020.101150_bib72","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing","volume":"133","author":"Kumar","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101150_bib73","first-page":"559","article-title":"Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time","volume":"17","author":"Kazandjian","year":"2019","journal-title":"Clin Adv Hematol Oncol : HO (Hum Organ)"},{"key":"10.1016\/j.beha.2020.101150_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32060","article-title":"Is there still a role for stem cell transplantation in multiple myeloma?","author":"Mina","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2020.101150_bib75","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1700900","article-title":"Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma","volume":"20","author":"Jagannath","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2020.101150_bib76","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:51Z","timestamp":1761498351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521692620300116"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101150","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies\u2014back to the future!","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101150"}}